AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the American Society of Hematology Annual Meeting are Now

  AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the
  American Society of Hematology Annual Meeting are Now Available

Business Wire

LEXINGTON, Mass. -- November 06, 2012

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that four abstracts
containing new data on treatment with Feraheme® (ferumoxytol) Injection for
intravenous (IV) use in patients with iron deficiency anemia with a history of
unsatisfactory oral iron therapy will be presented at the 2012 Annual Meeting
of the American Society of Hematology (ASH) taking place December 8-11, 2012
in Atlanta, Georgia.

The following abstracts have been accepted for presentation and are now
available on the ASH website at www.hematology.org:

  *“Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron
    Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron
    Therapy in a Phase III, Randomized, Placebo-Controlled Trial” (Vadhan-Raj,
    et. al.)
    Session Name: 102. Regulation of Iron Metabolism: Poster II; Date:Sunday,
    December 9, 2012
    Presentation Time: 6:00 PM - 8:00 PM; Location:Georgia World Congress
    Center, Hall B1-B2

  *“Potential New Treatment Option for Iron Deficiency Anemia Patients with a
    History of Unsatisfactory Oral Iron Therapy- Results of a Phase III,
    Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol” (Hetzel,
    et. al.)
    Session:102. Regulation of Iron Metabolism: Poster II; Date: Sunday,
    December 9, 2012
    Presentation Time: 6:00 PM-8:00 PM; Location: Georgia World Congress
    Center, Hall B1-B2

  *“Efficacy of Total Dose Administration (TDI) of 1012 Mg of Ferumoxytol
    Over 15 Minutes for the Treatment of Iron Deficient Anemia” (Auerbach, et.
    al.)
    Session Name: 102. Regulation of Iron Metabolism: Poster III; Date:
    Monday, December 10, 2012
    Presentation Time: 6:00 PM - 8:00 PM; Location: Georgia World Congress
    Center, Hall B1-B2
  *“Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue
    and Health-Related Quality of Life in Iron Deficiency Anemia Patients with
    a History of Unsatisfactory Oral Iron Therapy” (Vadhan-Raj, et. al.)
    Session Name: 901. Health Services and Outcomes Research: Benign
    hematology - iron metabolism, hemoglobinoapthies and coagulation;
    Session Date: Monday, December 10, 2012; Session Time: 10:30 AM - 12:00
    PM; Presentation Time: 11:15 AM; Room: Georgia World Congress Center,
    C211-C213

About Feraheme (ferumoxytol)

In the United States, Feraheme® (ferumoxytol) Injection for Intravenous (IV)
use is indicated for the treatment of iron deficiency anemia in adult chronic
kidney disease (CKD) patients. Feraheme received marketing approval from the
US Food and Drug Administration on June 30, 2009 and was commercially launched
by AMAG in the US shortly thereafter. Ferumoxytol received marketing approval
in Canada in December 2011, where it will be marketed by Takeda as Feraheme®,
and in the European Union in June 2012 and Switzerland in August 2012, where
it will be marketed by Takeda as Rienso®. For additional product information,
please visit www.feraheme.com.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® in the United States. For additional
company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.

The important safety information below is based on the United States
prescribing information.

Important Safety Information About Feraheme

Indication and contraindications

Feraheme is indicated for the treatment of iron deficiency anemia in adult
patients with chronic kidney disease. Feraheme is contraindicated in patients
with known hypersensitivity to Feraheme or any of its components.

Warnings and precautions

Serious hypersensitivity reactions, including anaphylactic-type reactions,
some of which have been life-threatening and fatal, have been reported in
patients receiving Feraheme. Observe patients for signs and symptoms of
hypersensitivity during and after Feraheme administration for at least 30
minutes and until clinically stable following completion of each
administration. Only administer the drug when personnel and therapies are
immediately available for the treatment of anaphylaxis and other
hypersensitivity reactions. Anaphylactic type reactions, presenting with
cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope,
and unresponsiveness have been reported in the post-marketing experience. In
clinical studies, serious hypersensitivity reactions were reported in 0.2%
(3/1,726) of subjects receiving Feraheme. Other adverse reactions potentially
associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing)
were reported in 3.7% (63/1,726) of subjects.

Severe adverse reactions of clinically significant hypotension have been
reported in the post-marketing experience. In clinical studies, hypotension
was reported in 1.9% (33/1,726) of subjects, including three patients with
serious hypotensive reactions. Monitor for signs and symptoms of hypotension
following each Feraheme injection. Excessive therapy with parenteral iron can
lead to excess storage of iron with the possibility of iatrogenic
hemosiderosis. Patients should be regularly monitored for hematologic response
during parenteral iron therapy, noting that lab assays may overestimate serum
iron and transferrin bound iron values in the 24 hours following
administration of Feraheme. As a superparamagnetic iron oxide, Feraheme may
transiently affect magnetic resonance diagnostic imaging studies for up to 3
months following the last Feraheme dose. Feraheme will not affect X-ray, CT,
PET, SPECT, ultrasound, or nuclear imaging.

Adverse reactions

In clinical trials, the most commonly occurring adverse reactions in Feraheme
treated patients versus oral iron treated patients reported in ≥ 2% of chronic
kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%),
dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs.
5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse
reactions leading to treatment discontinuation and occurring in 2 or more
Feraheme treated patients included hypotension, infusion site swelling,
increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis,
pruritus, chronic renal failure, and urticaria.

Post-marketing safety experience

The following adverse reactions have been identified during post-approval use
of Feraheme. Because these reactions are reported voluntarily from a
population of uncertain size, it is not always possible to reliably estimate
their frequency or establish a causal relationship to drug exposure.

The following serious adverse reactions have been reported from the
post-marketing spontaneous reports with Feraheme: life-threatening
anaphylactic-type reactions, cardiac/cardiorespiratory arrest, clinically
significant hypotension, syncope, unresponsiveness, loss of consciousness,
tachycardia/rhythm abnormalities, angioedema, ischemic myocardial events,
congestive heart failure, pulse absent, and cyanosis. These adverse reactions
have occurred up to 30 minutes after the administration of Feraheme injection.
Reactions have occurred following the first dose or subsequent doses of
Feraheme.

For full prescribing information, please visit www.feraheme.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts are forward-looking statements which involve risks and
uncertainties that could cause actual results to differ materially from those
discussed in such forward-looking statements.

Such risks and uncertainties include: (1) uncertainties regarding our and
Takeda's ability to successfully compete in the intravenous iron replacement
market both in the US and outside the US, including the EU, (2) uncertainties
regarding our ability to successfully and timely complete our clinical
development programs and obtain regulatory approval forFeraheme/Riensoin the
broader IDA indication both in the US and in territories outside of the US,
including theEU, (3) the possibility that significant safety or drug
interaction problems could arise with respect toFeraheme/Rienso, (4)
uncertainties regarding the ability to manufactureFeraheme/Rienso, (5)
uncertainties relating to our patents and proprietary rights, and (6) other
risks identified in ourSecurities and Exchange Commissionfilings, including
our Quarterly Report on Form 10-Q for the quarter endedJune 30, 2012. We
caution you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made.

We disclaim any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or circumstances
on which any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking
statements.

Contact:

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303